The in Vivo Metabolic Pattern of Low-grade Brain Gliomas: A Positron Emission Tomographic Study Using 18F-fluorodeoxyglucose and11 C-L-methylmethionine
- 1 February 1997
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 40 (2) , 276-288
- https://doi.org/10.1097/00006123-199702000-00009
Abstract
The object of the present study was to identify metabolic differences between low-grade astrocytomas and oligodendrogliomas and to improve their diagnosis and noninvasive assessment, because both types of tumors look very similar from the point of view of clinical and radiological data (as assessed by computed tomography and magnetic resonance imaging). Before any aggressive treatment, 22 patients with primary low-grade gliomas (astrocytomas in 12 patients and oligodendrogliomas in 10) were investigated with positron emission tomography for both glucose metabolism (18F-fluorodeoxyglucose) and amino acid uptake (11C-L-methylmethionine). An original software that allows a full metabolic analysis of the tumor region of interest (defined from the T1-weighted magnetic resonance image) and compares tumor tissue uptake tracer concentrations with average healthy tissue values has been implemented for data processing. Heterogeneity of each individual tumor has been taken into account and was expressed in histograms, which provided data about the mean and also extreme and intermediate values of tracer concentrations and the way these values are distributed among the full tumor mass. It has been shown that both tumor types exhibit a glucose hypometabolism (slightly more pronounced with astrocytomas), whereas they strongly differ in methionine uptake, which is high in all oligodendrogliomas and either decreased, normal, or moderately increased in astrocytomas. This latter metabolic difference between both tumor populations may be partially explained by their different cell densities. This study suggests that despite similar radiological and clinical presentations, these two kinds of low-grade gliomas are metabolically different and could therefore have specific responses to different therapies. Moreover, their in vivo metabolic follow-up with positron emission tomography should rely on different parameters, depending on their histological type; methionine uptake may be more relevant than glucose metabolism in the follow-up of oligodendrogliomas.Keywords
This publication has 25 references indexed in Scilit:
- Acute effect of carmustine on glucose metabolism in brain and glioblastomaCancer, 1994
- Correlation of glucose consumption and tumor cell density in astrocytomasJournal of Neurosurgery, 1993
- Positron Emission Tomography in the Detection of Malignant Degeneration of Low-Grade GliomasNeurosurgery, 1988
- Positron emission tomography in patients with glioma a predictor of prognosisCancer, 1988
- Rapid Decrease in Amino Acid Metabolism in Prolactin-Secreting Pituitary Adenomas After Bromocriptine TreatmentJournal of Computer Assisted Tomography, 1987
- Positron Emission Tomography Using [18F] Fluorodeoxyglucose in Brain Tumors A Powerful Diagnostic and Prognostic ToolInvestigative Radiology, 1987
- Positron Emission Tomography with ([11C]Methyl)-L-Methionine, [11C]D-Glucose, and [68Ga]EDTA in Supratentorial TumorsJournal of Computer Assisted Tomography, 1985
- A Stereotactic Method of Anatomical Localization for Positron Emission TomographyJournal of Computer Assisted Tomography, 1985
- Glucose utilization of cerebral gliomas measured by [ 18 F] fluorodeoxyglucose and positron emission tomographyNeurology, 1982
- Brain Tumor Imaging by Positron Emission Computed Tomography Using 11C-Labeled Amino AcidsJournal of Computer Assisted Tomography, 1982